Current research on anti-breast cancer synthetic compounds

Jia Liu,†a,b Bian Ming,†a,b Guo-Hua Gong,†c Di Wang,†a,b Gui-Lan Bao,*a,b and Li-Jun Yu*a,b

Breast cancer (BC) is the most common cancer for females and its incidence tends to increase year by year. Currently, the backbone of therapy for BC is mainly chemotherapy, however its toxicity in normal cells and acquired tumor resistance to the drug used are considered as the main barriers. Therefore, there is still an urgent need for the development of more effective and safer anti-BC agents. Based on previous reference documents in recent years, this review covers the work reported on the anti-BC compounds which are classified according to the structures. This review summarized 185 significant anti-BC compounds which are classified by functional groups according to the animal model data, although there would be some limitations with the data. This review highlights the properties of new compounds endowed with promising anti-BC properties, which may be proven to be more effective and selective, and possibly free of unwanted side effects. The reviewed compounds represent an interesting possibility to overcome BC and to reduce the percentage of patients with a poor response to drug therapy.

1. Introduction

Cancer is one of the crucial public health problems in the world. The corresponding incidence and mortality statistics shows that it is growing in the economically developing and developed countries.1,2 Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths, and is now also the leading cause of cancer death among females in economically developing countries.3 Environmental factors and dietary habits are the primary source of BC induction with some secondary factors like virus-mediated genetic disturbances and many more.3 During the development of cancer, multiple signaling cascades get deregulated which result in increased cell proliferation, cell survival, as well as the emergence of resistance towards several anticancer drugs. The deregulation mainly recognized in BC is the inactivation of tumor suppressor genes and hyperactivation of proto-oncogenes.4 BC can be described as a heterogeneous group of neoplasms originating from the epithelial cells and it as a complex disease has posed a great challenge to the field of medicine and immunology.5 As a result, it is evident that more effective therapy is needed to treat these malignancies.

For the treatment of BC, fulvestrant, lapatinib, eribulin mesylate, pertuzumab, everolimus and numerous other agents have been approved by the FDA for various BC subtypes treatments. The occurrence of resistance that is faced by these drugs has restricted their use, and we still need some alternates for a full proof treatment option against BC. Despite extensive research and rapid progress in cancer treatment, there is a need to develop a new group of anticancer agents targeting BC cells.6 Nowadays a large number of potent bioactive entities originating from natural sources as well as derived by synthetic methodology exist as potent anticancer agents that can be used for BC chemotherapy.7 This review summarizes the recent discovery of newly synthesized anti-breast cancer compounds that further promote our understanding of new synthetic compounds and provide a basis for further research in the future.

2. The quinoline functional group

Quinoline is nitrogen-containing heterocyclic aromatic compound. Pharmacologically active substances display a broad range of biological activity. Quinoline has been found to possess anti-malarial, antibacterial, antifungal, anticonvulsant, anti-inflammatory and analgesic activity.8–12 Quinoline derivatives are the pharmacologically important heterocycles which have been studied extensively for their anticancer properties.
Table 1  Quinoline anti-breast cancer compounds

<table>
<thead>
<tr>
<th>Compound no.</th>
<th>Substituent group</th>
<th>Reference no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2-Ph(4-NH&lt;sub&gt;2&lt;/sub&gt;), 7-Cl</td>
<td>13</td>
</tr>
<tr>
<td>2</td>
<td>2-Ph(4-F), 4-&lt;sub&gt;O&lt;/sub&gt;, 6,8-&lt;sub&gt;Br&lt;/sub&gt;&lt;sub&gt;2&lt;/sub&gt;, 7&amp;8= C Cyclohexyl</td>
<td>14</td>
</tr>
<tr>
<td>3</td>
<td>2-Ph(4-NO&lt;sub&gt;2&lt;/sub&gt;), 4-&lt;sub&gt;O&lt;/sub&gt;, 6,8-&lt;sub&gt;Br&lt;/sub&gt;&lt;sub&gt;2&lt;/sub&gt;</td>
<td>15</td>
</tr>
<tr>
<td>4</td>
<td>2-Ph(4-CN), 4-&lt;sub&gt;O&lt;/sub&gt;, 6,8-&lt;sub&gt;Br&lt;/sub&gt;&lt;sub&gt;2&lt;/sub&gt;</td>
<td>15</td>
</tr>
<tr>
<td>5</td>
<td>2-Ph(4-OH), 4-&lt;sub&gt;O&lt;/sub&gt;, 6,8-&lt;sub&gt;Br&lt;/sub&gt;&lt;sub&gt;2&lt;/sub&gt;</td>
<td>16</td>
</tr>
<tr>
<td>6</td>
<td>Cl</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>NH&lt;sub&gt;2&lt;/sub&gt;, 5=O</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>OCH&lt;sub&gt;3&lt;/sub&gt;, 2=O</td>
<td>17</td>
</tr>
<tr>
<td>9</td>
<td>OCH&lt;sub&gt;3&lt;/sub&gt;, 2=O</td>
<td>17</td>
</tr>
<tr>
<td>10</td>
<td>Cl</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>OCH&lt;sub&gt;3&lt;/sub&gt;, 2=O</td>
<td>17</td>
</tr>
</tbody>
</table>
Bharathkumar et al., prepared a novel type of quinoline-based estrogen receptor alpha (ERα) ligands were tested for their bioactivity against ERα-positive and ERα-negative cell lines. The strongest compound 1 displayed significant cytotoxicity against MCF-7 and HepG2 cells with an half maximal inhibitory concentration (IC50) value of 6 and 11 μM, respectively (Table 1).

A new group of 4-(imidazolylmethyl)quinoline derivatives were designed and synthesized as selective cyclooxygenase (COX-2) inhibitors and in vitro anti-BC agents. In anti-breast cancer screening, only one compound 2 (IC50 < 5 μM) was identified as the most potent and selective COX-2 inhibitor as well as the most cytotoxic agent against MCF-7 cells (Table 1). A series of novel 6,8-dibromo-2-aryl-2,3-dihydroquinolin-4(1H)-ones have been synthesized and evaluated in vitro (in MCF-7 BC cell lines). Compounds 3–6 exhibited potent growth inhibition of 50% (GI50) and total growth inhibition (TGI) values compared with reference standard (Table 1).

3-Amino-N-(3-chlorophenyl)-5-oxo-5,6,7,8-tetrahydrothieno[2,3-b]quinoline-2-carboxamide (compound 7) as a putative phosphoinositide specific-phospholipase C-γ enzyme inhibitor, affected the proliferation, morphology and migration of a host of breast cancer cell lines, and arrests cell cycle in the G2/M phases (Table 1).

A series of pyridinylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-i]quinolin-4-ones were designed and synthesized as a novel strategy for BC with elevated cardiovascular diseases. The compromise of this conflict led to compounds 8–11 as potent and selective dual inhibitors of aromatase (CYP19) and aldosterone synthase (CYP11B2), especially compound 11, which exhibited IC50 values of 32 and 41 nM, respectively, and a high selectivity toward 17α-hydroxylase-17,20-lyase and 11β-hydroxylase. Through the approach of combining important structural features of CYP19 and CYP11B2 inhibitors to design dual inhibitors, compounds 12 and 13 were obtained as selective dual inhibitors with IC50 values around 50 and 20 nM toward CYP19 and CYP11B2, respectively, similar to that of fadrozole as a reference (Table 1).

Mohammadhosseini et al., reported synthesis and cytotoxic activity evaluation of a new series of N-pipearzinyl quinolones containing N-2-(furyl-2 or 3-yl)-2-(chlorobenzyloxyimino)ethyl moiety. Preliminary screening indicated that compound 14 with IC50 values of 3.03, 11.9 and 2.2 for MCF-7, MDA-MB-231 and T47D, respectively demonstrated significant growth inhibitory potential against all evaluated cell lines (Table 1).

### 3. The quinazoline or quinazolinone functional groups

It is well known that quinazoline derivatives have a wide range of biological activities such as anticonvulsant, antibacterial, antiviral, antifungal, anticancer, analgesic and COX-2 inhibitors. Several quinazoline derivatives have been approved by FDA as anticancer drugs such as erlotinib, lapatinib, gefitinib and caneratinib.

6,8-Dibromo-2-(4-chlorophenyl)-quinazolin-4-one linked directly to oxadiazole, pyrazole or through amide linkage to thiazolidinone were synthesized, and evaluated their anti-BC activities.
Table 2  Quinazoline or quinazolinone anti-breast cancer compounds

<table>
<thead>
<tr>
<th>Compound no.</th>
<th>Substituent group</th>
<th>Reference no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>2-Ph(4-Cl), 3-Ph(4-COOH), 4-O, 6,8-Br₂</td>
<td>26</td>
</tr>
<tr>
<td>16</td>
<td>2-Ph(4-Cl), 6,8-Br₂, 4-O</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>2-Ph(4-Cl), 4-O, 6,8-Br₂</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>2-Ph(4-Cl), 4-O, 6,8-Br₂</td>
<td>27</td>
</tr>
<tr>
<td>19</td>
<td>2-Ph(4-Cl), 3-Ph(4-COOH), 4-O, 6,8-Br₂</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>2-Ph(4-Cl), 3-N, 4-O, 6,8-Br₂</td>
<td></td>
</tr>
<tr>
<td>Compound no.</td>
<td>Substituent group</td>
<td>Reference no.</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>21</td>
<td>2-NH₂, 4-O, 6-O, 8-OH</td>
<td>28</td>
</tr>
<tr>
<td>22</td>
<td>2-Ph(2-OH,5-Br), 4-O</td>
<td>29</td>
</tr>
<tr>
<td>23</td>
<td>2-Ph(2-OH,3-OCH₃,5-Br), 4-O</td>
<td>30</td>
</tr>
<tr>
<td>24</td>
<td>3-NH, 4-Bromo, 6-COO</td>
<td>30</td>
</tr>
<tr>
<td>25</td>
<td>3-NH, 4-Bromo, 6-COO</td>
<td>31</td>
</tr>
<tr>
<td>26</td>
<td>24-(=O)₂</td>
<td>32</td>
</tr>
<tr>
<td>27</td>
<td>4-NH, 6-CH₃CO</td>
<td>32</td>
</tr>
</tbody>
</table>

Table 2 (Contd.)
cell line (MCF-7) activity using doxorubicin as a reference drug. The most active compounds of the hybrid molecules between quinazolin-4-one and thiazolidinone are compounds 15–18 (IC$_{50}$ = 3–9 μM). In vitro screening of these four compounds against EGFR tyrosine kinases demonstrated inhibitory activity range 54–77.2% (Table 2).26

A new series of 6,8-dibromo-2-(4-chlorophenyl)quinazolin-4(3H)-one derivatives were synthesized and tested in vitro against human BC cell line (MCF-7). Compounds 19 and 20 exerted a powerful cytotoxic effect against MCF-7 with a very low IC$_{50}$ (1.5 and 4.7 μM), compared to doxorubicin (2.5 μM) (Table 2).27

A series of unknown 3-(alkyl(dialkyl)amino)benzofuro[2,3-f]quinazolin-1(2H)-ones has been synthesized as new ellipticine analogs. The cytotoxic activities of all the synthesized compounds, tested in ER$^+$, ER$^-$ and tamoxifen-resistant BC cell lines, revealed that DPA-HBFQ-1 (compound 21) was the most active compound via up-regulating the cell cycle regulators p53 and p21(Cip1/WAF1) and selectively inhibiting the human topoisomerase II (Table 2).28

Two new synthesized and characterized quinazoline Schiff bases 22 and 23 showed a remarkable antiproliferative effect for MCF-7 human BC cell line, with an IC$_{50}$ value of 6.246 mM and 5.910 mM, respectively, through inducing apoptosis pathway, activating caspases-3/7, -8, and -9 and inhibiting NF-κB translocation (Table 2).29

Two novel series of oxazolo[4,5-$g$]quinazolin-2(1H)-one derivatives as EGFR/HER2 dual inhibitors were synthesized and subjected to pharmacological evaluation. Compounds 24 and 25 with IC$_{50}$ value of 2.3 μM and 0.47 μM respectively had well exhibition to the EGFR and HER2 inhibition activity and excellent anti-proliferation activity against human lung adenocarcinoma cell line (A549) and human BC cell line (SK-BR3) comparing with lapatinib (Table 2).29

A novel series of 1-benzylquinazoline-2,4(1H,3H)-dione derivatives were designed and synthesized as human poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Compound 26 was a promising PARP-1 and PARP-2 inhibitor and could selectively kill the BC cells MX-1 (IC$_{50}$ = 4.59 μM) and MDA-MB-468 with mutated BRCA1/2 and PTEN, respectively, compared with homologous recombination proficient cell types such as BC cells MDA-MB-231 (Table 2).24

Jang et al.,31 discovered novel quinazoline analogues that had high potency and selectivity for BC cells. Derivative 27 (IC$_{50}$ = 8.8 × 10$^{-3}$ μM) was the most potent, with high selectivity for SKBr-3 over A431 cells by inhibiting EGFR and HER2 expressing (Table 2).

4. The pyridine functional group

Five and six-membered nitrogen-containing heterocycles are abundant in nature and exhibit diverse and important biological properties.35–37 Pyrazolopyridine derivatives are a significant class of heterocyclic compounds, which exhibit various biological activities including anticancer, anxiolytic, antiviral, antileishmanial and anti-inflammatory activities.38–40 Because of their biological activities, pyridines and substituted pyridines have distinguished themselves as heterocycles of profound chemical and biological significance.41

A series of novel 2H-pyrazolo[4,3-c]hexahydropyridine derivatives have been designed, synthesized and evaluated in vitro against two human BC cell lines. Most compounds exhibited good inhibition, and compounds 28 (IC$_{50}$ = 4.7 μM for MCF-7 and IC$_{50}$ = 9.3 μM for MDA-MB-231), 29 (IC$_{50}$ = 2.4 μM for MCF-7 and IC$_{50}$ = 4.2 μM for MDA-MB-231) and 30 (IC$_{50}$ = 3.3 μM for MCF-7 and IC$_{50}$ = 8.6 μM for MDA-MB-231) displayed better inhibitory activity than 5-fluorouracil (IC$_{50}$ = 4.8 μM for MCF-7 and IC$_{50}$ = 9.6 μM for MDA-MB-231, respectively) as the control. Moreover, 29 was cytotoxic and able to induced the apoptosis of MCF-7 cells (Fig. 1).41

Mohan et al.,42 reported the synthesis of trisubstituted-imidazoles and identified 2-chloro-3-(4,5-diphenyl-1H-imidazol-2-yl) pyridine (31) as lead cytotoxic agent. The lead compound 31 with IC$_{50}$ value of 0–50 μM for MCF-7 and MDA-MB-231 suppressed the proliferation of BC cells, decreased the phosphorylation of phosphoinositide-dependent kinase, Akt, Mammalian Target of Rapamycin (mTOR), downregulated the cellular invasion and activated caspases and cleaved PARP to induce apoptosis (Fig. 1).

A series of new diethyl(alkyl/aryl/heteroarylamino) (4-(pyridine-2-yl)phenyl)methylphosphonates were synthesized. The compounds 32–34 exhibited higher cytotoxicity against malignant BC MCF-7 cells via good inhibiting effect on the aromatase enzyme by virtue of their strong binding affinity through H-bonding with the amino acid residues of the enzyme (Fig. 1).43

Radi et al.,44 reported synthesis of novel β-keto–enol derivatives tethered pyrazole, pyridine and furan as new potential antifungal and anti-BC agents. In all compounds tethered pyridine, 35 had the most potent activity against BC with IC$_{50}$ values of 78.23 μM (Fig. 1).
5. The pyrimidine functional group

Pyrimidine ring is an aromatic heterocyclic organic compound similar to pyridine. One of the three diazines, six-membered heterocycles with two nitrogen atoms in the ring, has the nitrogens at positions 1 and 3 in the ring. Pyrimidines, a significant one of the heterocyclic compounds, have a broad spectrum of bioactivities (antibacteria, anticancer and anti-inflammatory and the like).45-47

It was reported that a series of 5-arylthieno[2,3-d]pyrimidines as anti-BC agents. In all the tested compounds 36 and 37 (Table 3) with IC\textsubscript{50} 9.8 nM and 10.2 nM respectively were the most active compounds in all the tested compounds, because of the deep interaction of these compounds in the back of ATP binding site and the extra hydrophobic interaction provided by para and meta dimethoxy groups in 36 and para dimethylamino group in 37.48

A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives were designed and synthesized. Compound 38 showed the highest inhibitory potency against the Src kinase and the most potent antiviability activity against the typical TNBC cell line MDA-MB-231 among all the synthesized compounds. Further kinase inhibition assays showed that this compound was a multikinase inhibitor and potently significantly inhibited Src (IC\textsubscript{50} = 0.9 nM) and MAPK signaling and markedly induced apoptosis in tumor tissues (Table 3).49

Novel pyrimidine phosphonate molecules were designed so as to inhibit aromatase, a potential target of BC. The ligand-receptor complex of compound 39 showed a best docking score of −15.776 kcal mol\textsuperscript{−1} among all. Hence, this compound was synthesized and tested in vitro against MDA-MB-231 adenocarcinoma BC cells and it exhibited excellent antiproliferative activity and also induced apoptosis (Table 3).50

The present study describes an alkaline water–ethanol mediated series of combinatorial synthesis of 2-amino-4-phenyl-5-H-indeno[1,2-d]pyrimidine-5-one derivatives. The selected synthesized compounds have been screened against the human BC cell line MCF-7, human colon cancer cell line HT29, and normal viro monkey cell line, out of which compound 40 (GI\textsubscript{50} = 22.8 μM) demonstrated significant potency toward human BC cell line (MCF-7) (Table 3).51

A novel thiazolopyrimidinone series of phosphatidylinositol 3-kinase (PI3K)-beta selective inhibitors has been identified. This chemotype has provided an excellent tool compound, 41 (IC\textsubscript{50} = 22.8 μM) (Table 3), that showed potent growth inhibition in the PTEN-deficient MDA-MB-468 breast cell under anchorage independent conditions, and it also demonstrated pharmacodynamic effects and efficacy in a PTEN deficient prostate cancer PC-3 xenograft mouse model.52

In the present study, a series of novel triazole linked N-(pyrimidin-2-yl)benzof[d]thiazol-2-amine were synthesized and evaluated for anticancer activity against MCF-7 BC cells. Among the compounds tested, promising compounds 42–45 (Table 3), under the concentration of 3 μM, 3.2 μM, 2.52 μM, 2.12 μM, respectively, caused most remarkable cytotoxicity against MCF-7 BC cells, by inducing apoptosis and affecting the expression of key proteins such as ERK1/2, NF-B and survivin that cause abnormal cell proliferation and up-regulate the activity of caspase-9.53

One compound, 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (46) induced growth arrest of most tumor cell lines, including a panel of BC cell lines, with GI\textsubscript{50} values ranging from 0.025 to 2 μM, as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5) (Table 3).54

Halogenated thieno[3,2-d]pyrimidines (47 and 48) with IC\textsubscript{50} value of 9 μM and 5.9 μM respectively are both toxic to the TNBC cell model MDA-MB-231 at low-micromolar concentrations, but that only for compound 47 can selectively triggers mitotic arrest (Table 3).55

6. The imidazole functional group

Imidazole and its derivatives are a class of 5-membered heterocyclic structure having two non-adjacent nitrogen atoms. Recent studies revealed that the substituted imidazole derivatives have attracted much attention due to their broad spectrum of pharmacological activities such as anti-inflammatory, anti-fungal, anticonvulsant.56-58

A series of novel aminosubstituted xantheno[1,2-d]imidazole derivatives have been designed and synthesized and their antiproliferative activity has been evaluated against human breast MDA-MB-231 cell line. Compounds 49–52 with IC\textsubscript{50} value of 46 μM, 28 μM, 16 μM and 18 μM respectively (Table 4) exhibited the highest antiproliferative activity of all the compounds tested.59

Lai et al.,60 described the identification and characterization of a series of small-molecule, orally bioavailable selective estrogen receptor degraders which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties. In anti-BC screening, candidate 53 (Table 4), the high efficacy degraderst, is currently in clinical trials in women with locally advanced or metastatic ER\textsuperscript{+} BC.

A series of novel substituted 2-(phenyl)-3H-benzo[d] imidazole-5-carboxylic acids and its methyl esters were synthesized and examined for their antiproliferative effects against three BC cell lines in vitro. Compound 54 (Table 4) bearing 5-fluoro-2-hydroxyphenyl substituent was found to be the most active derivative of the series with GI\textsubscript{50} values of 6.23, 4.09 and 0.18 μM against MDA-MB-468, MDA-MB-231 and MCF-7 BC cell lines, respectively.61

A new series of N-sec/tert-butyl 2-arylimidazolimidazole derivatives was synthesized and evaluated for antiproliferative activity against MCF-7 and MDA-MB-231. The most potent inhibition against MDA-MB-231 human BC cell line came from compound 55 (Table 4) with IC\textsubscript{50} of 29.7 μM.62

A series of new isatin-thiazoline and isatin-benzimidazole derivatives were synthesized and assessed the anti-BC activity. The results showed that compounds 56–58 with IC\textsubscript{50} value of 24.95 × 10\textsuperscript{−3} μM, 26.36 × 10\textsuperscript{−3} μM and 22.59 × 10\textsuperscript{−3} μM respectively (Table 4) possessed significant antiproliferative activity against MCF-7 cells.63
<table>
<thead>
<tr>
<th>Compound no.</th>
<th>Substituent group</th>
<th>Reference no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>36</td>
<td></td>
<td>48</td>
</tr>
<tr>
<td>37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td></td>
<td>49</td>
</tr>
<tr>
<td>39</td>
<td></td>
<td>50</td>
</tr>
<tr>
<td>40</td>
<td></td>
<td>51</td>
</tr>
<tr>
<td>41</td>
<td></td>
<td>52</td>
</tr>
<tr>
<td>Compound no.</td>
<td>Substituent group</td>
<td>Reference no.</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>42</td>
<td><img src="image1" alt="Chemical structure" /></td>
<td>53</td>
</tr>
<tr>
<td>43</td>
<td><img src="image2" alt="Chemical structure" /></td>
<td></td>
</tr>
<tr>
<td>44</td>
<td><img src="image3" alt="Chemical structure" /></td>
<td>53</td>
</tr>
<tr>
<td>45</td>
<td><img src="image4" alt="Chemical structure" /></td>
<td></td>
</tr>
<tr>
<td>46</td>
<td><img src="image5" alt="Chemical structure" /></td>
<td>54</td>
</tr>
<tr>
<td>47</td>
<td><img src="image6" alt="Chemical structure" /></td>
<td>55</td>
</tr>
<tr>
<td>48</td>
<td><img src="image7" alt="Chemical structure" /></td>
<td></td>
</tr>
</tbody>
</table>
7. The tetrazolium functional group

Tetrazole, a heterocyclic compound, contains a carbon atom and four nitrogen atoms in a five-membered ring. Theoretically there are three precursor tetrazole isomers: 1H-tetrazole, 2H-tetrazolium and 5H-tetrazole. Substituted tetrazoles exist as a nearly 1:1 ratio of 1H- and 2H-tautomeric forms. Previous studies had indicated that the two positional isomers may be differentiated on the nuclear magnetic resonance (NMR) timescale. 44 Tetrazole and its derivatives have a variety of activities, such as anti-tumor, antioxidant, antinociceptive, antibacterial and anti-inflammatory because of their unique structure. 65–68

A series of new 1,2-substituted tetrazole derivatives were synthesized and evaluated on MCF-7 (ER positive), MDA-MB-231 and ZR-75 (ER negative) BC cell lines. Compounds 59–61 showed higher inhibitory effects on MCF-7 cells, while compound 62 exhibited a higher inhibition on MDA-MB-231 cells and ZR-75 cells at a concentration of 10 μM (Fig. 2). 69

Köhler et al., 70 synthesized 21 derivatives of the third-generation P-glycoprotein (P-gp, ABCB1) inhibitor HM30181, which is structurally related to tariquidar. The compounds were tested for their inhibitory activities against the BC resistance protein (BCRP, ABCG2) and screened against P-gp and multi-drug resistance protein 1 (MRP1, ABCC1) to confirm the selectivity toward BCRP. Compounds 63–65 led to a maximal response comparable to that of the standards the reference inhibitors XR9577 and Ko143. Compounds 66–68 are selective toward BCRP with about 2-fold higher inhibitory activities than the reference Ko143, which is the most potent BCRP inhibitor so far (Fig. 2).

### Table 4: Imidazole anti-breast cancer compounds

<table>
<thead>
<tr>
<th>Compound no.</th>
<th>Substituent group</th>
<th>Reference no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>54</td>
<td>2-Ph[2-OH,5-F], 5-COOCH3</td>
<td>61</td>
</tr>
<tr>
<td>55</td>
<td>1-CHC2H5(CH3), 2-Ph, 5-CO2Et</td>
<td>62</td>
</tr>
<tr>
<td>56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>57</td>
<td></td>
<td>63</td>
</tr>
<tr>
<td>58</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This journal is © The Royal Society of Chemistry 2018
8. The indole or isatin functional groups

Indole ring system as one of the most ubiquitous heterocycles in nature, has been becoming an important structural component in many pharmaceutical agents, such as anticonvulsant, antifungal, antiviral and anti-inflammatory, particularly in discovery of new antitumor agents. A variety of indole derivatives, such as isatin, have also been explored their anticancer activity. Moreover, indoles have promising anti-cancer potential; there has been the emphasis on the synthesis of indole derivatives to overcome problems faced by existing therapeutic agents.

A series of indeno[1,2-b]indole-9,10-dione derivatives were synthesized as human casein kinase II (CK2) inhibitors. Comparison the relative ability of each compound to inhibit CK2, compound 69 (IC₅₀ = 25 × 10⁻³ µM) (Table 5) has a distinct antiproliferative effect against MCF-7 BC cells and was about orders of magnitude more selective.

The indole alkaloid meleagrin (70) IC₅₀ value of 1.9, 6.8, 8.9, 2.7 and 2.8 µM respectively for MCF-7, MDA-MB-231, MDA-MB-468, BT-474 and SKBR-3 (Table 5), from the olive tree endophytic fungus *Penicillium chrysogenum*, was identified as a significant wild and mutant c-Met inhibitor. This was correlated with antiproliferative, antimitotic, and anti-invasive activities against a wide panel of c-Met dependent BC cells including all cell lines but was inactive against the c-Met independent BC cells.

The design, synthesis, inhibitory potency in *vitro* and pharmacokinetic profiles of Ko143 analogs are described. Compared to commonly used Ko143, the new BCRP inhibitor (compound 71) (Table 5) showed the same potency and a significantly improved pharmacokinetic profile in rats.

A research designed and synthesized novel neotanshinlactone analogues in order to inutilize bioisosterism and molecular modification, and to evaluate their bioactivity as anti-BC agents. Compound 72 (Table 5) has been tested for the three non-BC cell lines and the triple negative BC cell lines, but has exhibited no significant cytotoxicity with the average IC₅₀ being greater than 34 µM, compared to neo-tanshinlactone and 4-ethyl neotanshinlactone, and the selectivity towards BC has also diminished.

A series of novel benzothiazole derivatives bearing indole-based moiety were designed, synthesized and screened for *in vitro* antitumor activity against four cancer cell lines. Compound 73 (Table 5) exhibited excellent antitumor activity with IC₅₀ values of 0.024, 0.29, 0.84 and 0.88 µM against HT29, H460, A549 and MDA-MB-231, respectively. In addition, the marked pharmacological activity of compound 73 might be ascribed to activation of procaspase-3 and cell cycle arrest.

A series of novel indolylquinones have been synthesized and evaluated for their antiproliferative activity against human MDA-MB-231 and MCF-7 BC cell lines. Among all these derivatives, 74 (IC₅₀ value = 2.29 µg mL⁻¹ for MCF-7 cells) and 75 (IC₅₀ value = 3.99 µg mL⁻¹ for MDA-MB-231 cells) displayed the most potent antiproliferative activity of the series and inhibited BC cells proliferation by triggering apoptotic cell death (Table 5).

In the recent study, the synthesis of a novel synthetic aryl methyl ring substituted analog of 3,3-diindolyl methane, named as phemindole (76) [IC₅₀ = 10.85] was reported as an effective anti-tumor agent against MDA-MB-231 cells through inducing apoptosis and restricted the *in vitro* cell migration through its antimitotic property and the phosphorylation of focal adhesion kinase regulation in MDA-MB-231 cells. Furthermore, studies extended to *ex vivo* and *in vivo* mice models further validated the efficacy of phemindole.

A series of ten novel isatin analogs have been synthesized and screened *in vitro* for their anti-BC activity against MCF-7 cell line. All the tested compounds showed highly potent activity against MCF-7 BC cell line with especially compounds 77–80 (Table 5) exhibited demonstrative antiproliferative effects on MCF-7 BC cell line compared to reference adramycin (doxorubicin) and GI₅₀ < 0.02 µM.

A novel series of 3-(2-oxo-2-phenylethyldiene)indolin-2-ones incorporating pharmacophoric elements of isatins and chalcones were designed and synthesized and evaluated for anti-cancer activity against three BC cell lines. In all the promising compound, compound 81 (Table 5) was found to be the most active in the series with GI₅₀ values of 8.54, 4.76 and 3.59 µM against MDA-MB-231, MDA-MB-468 and MCF-7 cells, respectively.

9. The miscellaneous functional groups of organic compounds

Bhat *et al.*, reported a new series of 2-cylohexyl-N-[(Z)-substituted phenyl/furan-2-yl/thiophene-2-yl]methyliden]-hydrazinecarbothioamide derivatives. Compound 82 (Fig. 3) markedly inhibited the cell migration and cell adhesion of MDA-MB-231, MDA-MB-468, SKBR-3 and MCF-7 BC cell lines with an IC₅₀ value of 88.89 µM, 46.66 µM, 30.94 µM and 49.90 µM, respectively.

Mudjupa *et al.*, designed 4-[2-(3-[4-(trifluoromethyl)phenyl]thiazol-2-ylureido)vinyl]-1,2-phenylene dicacetate (compound 83), a small molecule EGFR inhibitor in *silico* by using caffeic scaffold as core structure, inhibited the growth of EGFR-overexpressing MDA-MB-468 triple-negative BC cells.
Table 5  Indole or isatin anti-breast cancer compounds

<table>
<thead>
<tr>
<th>Compound no.</th>
<th>Substituent group</th>
<th>Reference no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>73</td>
<td>1-CH₂Ph(4-Cl),</td>
<td>81</td>
</tr>
<tr>
<td>74</td>
<td>2-CH₃, Cl-Phe(4-Cl)</td>
<td>82</td>
</tr>
<tr>
<td>75</td>
<td>2-Ph(4-CH₃), Br</td>
<td>83</td>
</tr>
<tr>
<td>76</td>
<td>OH, 3, 7-CH₃</td>
<td>84</td>
</tr>
<tr>
<td>77</td>
<td>2-=O, N₃</td>
<td></td>
</tr>
<tr>
<td>78</td>
<td>2-=O, N₃</td>
<td></td>
</tr>
</tbody>
</table>
(TNBC) and wild-type non-small-cell lung cancer H460 cells via programmed cell death and suppressed EGFR expression. Alternatively, compound 83 may be able to decrease hormone receptors, ER and PR expression in the invasive MCF-7 cancer cells resulting in the potent anti-tumor activity (Fig. 3).

Weldon et al., synthesized a series of cinnamylideneacetophenones via a modified Claisen–Schmidt condensation reaction and evaluated for cytotoxicity against BC cells using the Alamar Blue™ assay. Derivatives 84 and 85 (Fig. 3) displayed significantly exhibited cytotoxicity against MDA-MB-468 and MCF-7 cells in the nanomolar to sub-micromolar range yet exhibited substantially less cytotoxicity in non-tumorigenic MCF-10A cells. In fact, the selectivity index for both compounds appears to be superior to that observed with the established chemotherapeutic agent doxorubicin.

Sala et al., synthesized a library of 2,3-thiazolidin-4-one derivatives which showed strong inhibitory effects on BC cell growth. Among all tested compounds 86 and 87 showed cytotoxic activity on MCF-7 cells while in SKBR3 cells compounds 88–90 determined a significant inhibition starting from the lowest dose (Fig. 3).

Parihar et al., synthesized twenty two combretastatin A4 analogues on steroidal framework from gallic acid with a possibility of anti-BC agents. Among these, compound 91 (Fig. 3) was the most active in MCF-7 by inducing apoptosis and MDA-MB-231 cells with IC₅₀ of 7.5 mM and 5.5 mM respectively and showed potent antitubulin effect. Docking experiments also supported strong binding affinity of 91 to microtubulepolymerase and was found to be non-toxic up to 300 mg kg⁻¹ dose in Swiss albino mice in acute oral toxicity.

Kaur et al., described the synthesis of some novel ospemifene derived analogs and their evaluation as anti-BC agents against human BC cell lines. Compound 92 was relatively more cytotoxic to MCF-7 cell lines similar to ospemifene and tamoxifen, while most potent compounds 93 and 94 were equally effective in inhibiting growth of both MCF-7 (ER-positive) and MDA-MB-231 (ER-negative) human BC cell lines (Fig. 3).

A series of 2-aryl-3-nitro-2H-chromenes were synthesized tested against BC cell lines including MCF-7, T-47D and MDA-MB-231. Representatively, compound 95 with IC₅₀ = 0.2 μM against MCF-7 cells, was 36-times more potent than etoposide, and antitumor activity for selected compounds 95 and 96 are identified by apoptosis pathway (Fig. 3).

A series of 3-substituted-4-chloro-thioxanthones and their corresponding S,S-dioxidethioxanthone derivatives were designed and synthesized and the inhibition activities of the synthesized compounds on cell viability were evaluated. Among the synthesized compounds, compound 97 (with a 4-chlorophenylthio group) was the most-active compound exhibiting potent inhibitory activity on the cell viability of MCF-7 and

<table>
<thead>
<tr>
<th>Compound no.</th>
<th>Substituent group</th>
<th>Reference no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>79</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80</td>
<td></td>
<td></td>
</tr>
<tr>
<td>81</td>
<td></td>
<td></td>
</tr>
<tr>
<td>85</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Compound no.</th>
<th>Substituent group</th>
<th>Reference no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>79</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80</td>
<td></td>
<td></td>
</tr>
<tr>
<td>81</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 5 (Contd.)
MDA-MB-468 cell lines with respective IC_{50} values of 7.2 and 3.9 μM (Fig. 3).

Varela et al., synthesized some already identified exemestane metabolites. All the studied metabolites reduced cell viability of MCF-7aro cells in a dose and time dependent manner, and metabolite 98 (Fig. 3) in much lower concentrations than the other metabolites and even exemestane dramatically decrease MCF-7aro cells viability. Therefore, their data suggest for the first time that exemestane originates active metabolites after metabolic transformation, which are also able to inhibit aromatase and reduce hormone-dependent BC cells viability.

A targeted library of constrained tricyclic compounds (three prototypes I, II, and III) of substituted dibenzo[b,f]thiepine and dibenzo[b,f]oxepines and structurally analogous to tamoxifen were synthesized as a new class of anti-BC agents. Of all the compounds tested, 101 (Fig. 3) exhibited potent in vitro anti-proliferative activity at 1.33 μM and 5 μM concentration in MCF-7 and MDA-MB-231 cell lines.

Meneni et al., synthesized a series of 5-alkynyl-20-deoxyuridines tested for antiproliferation properties against MCF-7 and MDA-MB-231 human mammary carcinoma cell lines. Compound 102 (Fig. 3), the only nucleoside in the series containing a terminal acetylene, showed the highest potency with IC_{50} (μM) 0.4 ± 0.3 for MCF-7 and 4.4 ± 0.4 for MDA-MB-231 exceeding cisplatin and 5-fluorouracil.

Nikolić et al., reported the synthesis of steroidal 16,17-seco-16,17α-dinitriles and investigated their antitumor cell properties. Strikingly, 103 (Fig. 3), a 1,4-dien-3-on derivative, displayed selective submicromolar antiproliferative activity against both MCF-7 and MDA-MB-231 BC cells (IC_{50} 0.52, 0.11 μM, respectively).

**Fig. 3** Structure of compounds 82–103.
Dyari et al.,\textsuperscript{99} reported the synthetic ω-3 epoxides (104–106) of saturated fatty acids as antiproliferative and proapoptotic agents in MDA-MB-231 BC cells. Compounds 104–106 impaired ATP production, enhanced caspase-3 activity, and activated c-jun-N-terminal-kinase signaling, leading to cyclin D1 down-regulation and cell cycle arrest in G1-phase. Fatty acid ω-3 monoepoxides may represent a novel class of antitumor agents (Fig. 4).

Wang et al.,\textsuperscript{100} prepared a series of artemisinin monomers and dimers by using the Ugi reaction, a convenient synthesis. With BT-474 cell lines, all the Ugi dimers showed remarkable activities. Especially, dimer 107 (Fig. 4) showed an IC\textsubscr{50} value of 12 nM, approximately more than 600 times more potent than artesunate as a positive control, and a low toxicity when tested on MCF-10A, a nontumorigenic cell line.

Mani et al.,\textsuperscript{101} synthesized compound 108 (Fig. 4) which impaired invasion migration and adhesion in breast MDA-MB-231, inhibiting matrix metalloproteinase breakdown of the extracellular matrix and its activity, also impairing metastasis to the lungs with only four of the treated mice showing severe or marked metastasis, in comparison to ten for the untreated mice.

Novel aza-resveratrol analogs were synthesized, structurally characterized and evaluated for cytotoxic activity against BC cell lines, which exhibited superior inhibitory activity than parent resveratrol compound. Compounds 109 and 110 exhibited most potent activity with IC\textsubscr{50} value of 21 and 29 μM against MDA-MB-231 (with 65–75% cytotoxicity) and 32 and 44 μM against T47D cells (Fig. 4).\textsuperscript{102}

![Fig. 4 Structure of compounds 104–125.](image-url)
Saha et al., synthesized, prepared and evaluated in vitro the first estrogen–doxorubicin conjugates at 16 aposition of estradiol termed E–DOXs. The IC_{50} of E–DOX 111 (Fig. 4) on ER\textsuperscript{+} MCF-7 and HT-29 human colon carcinoma cells are 14 and 18 \mu M, respectively whereas it is mainly inactive (>50 \mu M) on M21 human skin melanoma and ER\textsuperscript{-} MDA-MB-231 cells, showing that the selectivity of 111 is potentially a promising conjugate to target ER\textsuperscript{+} BC.

Salamone et al., synthesised new derivatives of troglitazone. Compounds 112 and 113 indicated good micromolar activity against hormone-dependent (MCF-7) and hormone-independent (MDA-MB-231) BC cell lines and poor toxicity towards hepatocytes in comparison to troglitazone (Fig. 4).

A set of 2-galactosylthiazolidine-4-carboxylic acid amides was synthesised. For the derivatives tested, the compound 114 (Fig. 4) is the highest activity with an IC_{50} of 17.0 \mu M for A375 melanoma and 5.8 \mu M for MCF-7 cell lines and also showed cytotoxicity against triple negative cancer cell line HCC1806. What’s more, the compound showed the activation of apoptotic pathways and also DNA damages with blockage of the cell cycle in the S-phase and appearance of peaks in G0/G1-phase.

The novel unnatural lupulone derivatives were synthesised found to be more toxic to MDA-MB-231 cell lines than the parent lupulone itself. Interestingly the most potent derivative 115 demonstrated an enhanced PARP cleavage for MDA-MB-231 cells while derivative 116 shows a significantly greater effect upon MCF-7 cells (Fig. 4).

A series of difluorinated propanediones were synthesized and evaluated for in vitro cytotoxic activity on the 4-cell line panel consisting of MCF-7 (BC), HOP62 (lung cancer), A498 (renal cancer) and MIAPACA2 (pancreatic cancer). Compounds 117 and 118 showed favorable anti-proliferative activity in all of the four tested cancer cell lines (Fig. 4).

Ortho-, meta- and para-tyrosine–chlorambucil analogs were synthesized in order to generate new anticancer drugs with structural diversity. The m-tyrosine–chlorambucil hybrids (119 and 120) showed greater cytotoxicity compared to the other regiosomers (Fig. 4).

Novel plumbagin hydrazonates were prepared, structurally characterized and evaluated for anti-proliferative activity against the BC cell lines. Compounds 121 and 122 were especially promising against triple negative MDA-MB-231 (IC_{50} values 1.9 and 2.1 \mu M, respectively) and MDA-MB-468 BC cell lines via inhibiting NF-B expression (Fig. 4).

The synthesis of novel triarylethylene analogs, designed based on well-known Selective Estrogen Receptor Modulators, as potential anti-BC agents is described. Compounds 123 and 124 exhibited remarkable activity against both MCF-7 and MDMAB-231 cell lines, whereas the oxalamide 125 was selectively active against MDA-MB-231 cells (Fig. 4).

Neo-tanshinlactone derivatives (126–130) (Fig. 5) exerted potent and selective anti-breast cancer activity with IC_{50} values of 0.3, 0.2, 0.1 and 0.1 \mu M, respectively, against the ZR-75-1 cell lines. Importantly, analog 127 had an approximately 12-fold ratio of SKBR3/MCF-7 selectivity. Analog 128, 23 times more active against ZR-75-1 than MCF-7, exhibited high selectivity. In addition, analog 130 showed potent activity against a ZR-75-1 xenograft model, and high selectivity against breast cancer cell line compared with normal breast tissue-derived cell lines.

A novel series of letrozole analogs was designed and synthesized to find new potential anti-breast cancer agents. Cytotoxicity evaluation revealed that compounds 131 and 132 (Fig. 5) were the most potent compounds with comparative activity with etoposide.

A series of five analogous compounds based on the structure of piperlongumine were designed, synthesized and evaluated in cell migration and cytotoxicity assays. Among these, the analogue designed by molecular simplification (133) (Fig. 5) was the most active of the series, with an EC_{50} of 1.5 \pm 1 \mu M.

A series of novel substituted pyridopyrazine derivatives have been rationally designed and evaluated as multi-kinase

![Fig. 5 Structure of compounds 126–140.](image-url)
inhibitors in the PI3K pathway. The most potent compound 134 (Fig. 5) showed low micromolar cytotoxic potency in all BC cell lines and inhibited the growth of a HER2 amplified BC xenograft tumors. Analysis of excised tumors from the treated animals showed a significantly reduced population of Ki-67 positive cells and down-regulated levels of phosphorylated AKT, ERK1/2 and SRC compared to vehicle treated animals. Finally, the specificity of 89 was assessed in a panel of 31 kinases where a mild, but direct, inhibition of the MET receptor tyrosine kinase was observed.

Novel flavone derivatives were synthesized, characterized and examined for their antitumor activities against breast cancer cell lines. In initial screening, analogs 135 and 136 (Fig. 5) were found to be effective against the estrogen receptor negative cell line (MDA-MB-453). A novel synthetic compound 137 (Fig. 5), an analog of a naturally-occurring marine compound, was found to be the most active out of more than 40 related compounds. In a dose dependent manner, it inhibited cell growth and induced apoptosis and cell cycle arrest in human MCF-7 and MDA-MB-468 breast cancer cells in vitro, and showed in vivo efficacy in mice bearing MCF-7 or MDA-MB-468 xenograft tumors. Preclinical data indicated that 137 was a potential therapeutic agent for breast cancer that has multiple hormone-, Her-2- and p53-independent mechanisms of action.

New synthetic α-methylene-β-lactones were tested cytotoxicity and anticancer activity in comparison to paclitaxel as a positive control. The most potent compound 138 (Fig. 5) reduced the activity of viable MDA-MB-231 and MCF-7 cells (IC50 values of 5.3 μM and 3.54 μM, respectively). It activated the intrinsic pathway of apoptosis, related to the loss of mitochondrial membrane potential and changes in BAX/Bcl-2 ratio and also suppressed the movement of both types of breast cancer cells. Suppression of cell migration and invasion was the result of the decreased secretion of enzymes responsible for the degradation of the extracellular matrix, metalloproteinase-9 and urokinase plasminogen activator.

A series of 6-aryl-indenoisoquinolone derivatives as dual ERα and vascular endothelial growth factor receptors (VEGFR)-2 inhibitors were synthesized and evaluated. These compounds possessed good ERα binding affinity and ERα antagonistic activity and potent VEGFR-2 inhibitory potency, as well as excellent anti-proliferative activities against MCF-7, MDA-MB-231, Ishikawa and HUVEC cell lines. Among these, compound 139 (Fig. 5) may inhibit the activation of VEGFR-2 and the signaling transduction of Raf-1/MAPK/ERK pathway in MCF-7 cells.

Novel N-(guanidinyl)benzenesulfonanilides were prepared and evaluated for their anticancer activity against human tumor breast cell line (MCF-7). It was found that the most potent compounds was 139 (IC50 values = 49.5 μM) (Fig. 5).

10. The ferrocenyl functional group

Ferrocene possesses many chemical properties, one of which is robust enough to be functionalized on its cyclopentadienyl rings. Because of it, an electron acceptor, disrupting electron transfer in biological systems, ferrocenyl derivatives have been found to possess biological activity, for instant, antitumour, antimalarial, antibacterial, and antifungal activity. Eight ferrocenyl derivatives were synthesized and assessed the anti-BC activities. Of the eight compounds, only compounds 141 (IC50 value of 56 and 61 μM respectively for MCF-7 and MDA-MB-231) and 142 (IC50 value of 47 and 87 μM respectively for MCF-7 and MDA-MB-231) showed cytotoxicity in both MCF-7 and MDA-MB-231 cell lines (Table 6).

Tan et al. synthesized and assessed anti-tumoral properties of a series of compounds possessing a ferrocenyl group tethered to a catechol through a conjugated system. Compound 143 (IC50 = 0.48 μM for MDA-MB-231) (Table 6) displayed the highest anti-proliferative effect amongst the catechol complexes.

Gao et al. established a synthesis and cytotoxic properties of ferrocenyl ester derivatives, varying the lipophilic character of the pendant groups. Compound 144 (Table 6) showed the best IC50 values, 180 μM for HT-29 and 190 μM for MCF-7 cell lines, with cytotoxicities similar to ferrocene and ferrocenium for comparison.

1-p-(Ferrocenylcarbamylamino-phenyl)-1,2-di(p-hydroxyphenyl)-but-1-ene (145) was synthesized and exhibited a significant antiproliferative activities against MCF-7 and MDA-MB-231 BC cells with 4.53 μM and 1 μM, respectively (Table 6).

Zheng et al. synthesized a series of novel Selective Estrogen Receptor Modulators (SERMs) bearing a ferrocenyl unit based on a three-dimensional oxabicyclo[2.2.1]heptene core scaffold. The antiproliferative effects of compounds 146-148 (IC50 value of 5.6, 10.4 and 7.5 μM respectively for MCF-7 and IC50 value of 12.2, 126 and 7.8 μM respectively for MDA-MB-231) (Table 6) on MCF-7 cells line does not arise from antiestrogenicity, but rather proceeds through a cytotoxic pathway.

A new class of indeno[1,2-c]isoquinolines containing the ferrocenyl scaffold was synthesized. The most potent compound 149 (Table 6) with IC50 of 0.95 μM displayed high DNA interaction, topoisomerase I and II inhibition, and an in vitro cytotoxicity comparable to etoposide as the reference drug.

de Jesús Cazares-Marinero et al. synthesized seven new ferrocenyl compounds which showed strong antiproliferative activities against BC cell lines with IC50 values ranging from 0.5 μM to 4.12 μM. Primary amides FeTAMPSA (compound 150) and 151 were the most cytotoxic compounds of all the three series (succinic, adipic and succinic) against MDA-MB-231 cells, with IC50 values of 0.50 μM and 0.54 μM, respectively; while succinimide 152 was the most active compound against hormone dependent MCF-7 BC cells (Table 6).

Heilmann et al. synthesized four new ferrocene compounds and show strong cytotoxic effects against both the hormone-dependent MCF-7 and hormone-independent MDA-MB-231 BC cell lines. Compound 153 showed cytotoxic effects similar in magnitude to those observed with previously...
### Table 6 Structures of compounds 141–156

<table>
<thead>
<tr>
<th>Comp. no.</th>
<th>R</th>
<th>R&lt;sub&gt;1&lt;/sub&gt;</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>141</td>
<td>R&lt;sub&gt;1&lt;/sub&gt;=Ph</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>R&lt;sub&gt;2&lt;/sub&gt;=CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>R&lt;sub&gt;3&lt;/sub&gt;=OCH&lt;sub&gt;3&lt;/sub&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>142</td>
<td>R&lt;sub&gt;1&lt;/sub&gt;=4-methoxybenzene</td>
<td>R&lt;sub&gt;2&lt;/sub&gt;=H</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R&lt;sub&gt;3&lt;/sub&gt;=OCH&lt;sub&gt;3&lt;/sub&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>143</td>
<td></td>
<td>HO</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>144</td>
<td></td>
<td>R=</td>
<td></td>
</tr>
<tr>
<td>145</td>
<td></td>
<td>HO</td>
<td></td>
</tr>
<tr>
<td>146</td>
<td></td>
<td>HO</td>
<td></td>
</tr>
<tr>
<td>147</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>148</td>
<td></td>
<td>HO</td>
<td></td>
</tr>
<tr>
<td>149</td>
<td></td>
<td>HO</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
described ferrocenyl diphenol 154 (IC50 (153) = 0.5 μM; IC50 (154) = 0.6 μM) (Table 6).

Pigeon et al.,134 investigated the synthesis, cell proliferation effects, and electrochemical behavior of the ferrocenyl aniline 155 and acetanilide 156. Both compounds showed dual estrogenic/cytotoxic activity at concentrations 10 μM on the MCF-7 cell line, whereas antiproliferative with IC50 values of 0.8 μM and 0.65 μM, respectively, on the MDA-MB-231 cell line (Table 6).

### 11. The titanocene functional group

Several platinum agents, such as cisplatin, which exert antiproliferative activity in BC targeting DNA,135 have produced a strong interest in research of new organometallic compounds as pharmacological anticancer tools. Even though cisplatin and follow-on derivatives are still widely used in the clinic, the onset of toxic side effects and/or chemoresistance represents the principal limitation to their therapeutic efficacy.136,137 Within this context, the antitumor properties of different metal complexes have been evaluated and, amongst them, titanium complexes have received considerable attention because of their cytotoxic activity against solid tumors.138 During the recent years a plethora of modified titanium-based compounds have been synthesized and studied as potential antitumor agents, especially.138–141

Sirignano et al.,142 has prepared a series of novel titanocene-complexes and evaluated for their growth regulatory effects in MCF-7 and SkBr-3 BC cells. Among these compounds, that showed moderate to high antitumor activity, the strongest antiproliferative activity against MCF-7 cells was displayed especially by compound 157, whereas 158 elicited relevant repressive effects on SkBr3 cells (Table 7).

de la Cueva-Alique et al.,143 reported on the synthesis and characterization of a novel family of chiral cyclpentadienyl ammonium- or amino-oximato titanium derivatives.
Compounds 159 and 160 (IC$_{50}$ > 100 μM for MDA-MB-231) (Table 7) are more cytotoxic than additive doses of titanocene dichloride and free oxime proligand, against human renal Caki-1, colon DLD-1 and MDA-MB-231 cell lines.

Saturnino et al., evaluated some synthesized titanocene-complexes, having an ethenyl-phenoxide or a benzyl group as substituents of the cyclopentadienyl rings for their cytotoxic potential against MCF-7 and SkBr-3 human BC cell lines. Compounds 161–163 (IC$_{50}$ value of 10, 9 and 10 μM respectively for MCF-7 and IC$_{50}$ value of 10, 6 and 10 μM respectively for SKBR-3) (Table 7) have shown significant anti-proliferative effects, compared to cisplatin.

Chimento et al., reported the synthesis of some new titanocene and half-titanocene compounds having a methyl group on the carbon 6 and a methoxy-naphthyl group as substituent of the cyclopentadienyl. Moreover, the IC$_{50}$ values of the most active compounds (i.e., 164–166) and of cisplatin have been calculated, evidencing that these new complexes 164–166 (IC$_{50}$ value of 85.26, 49.16 and 129.8 μM respectively for MCF-7) exerted antiproliferative effect on MCF-7 BC cells, via inhibiting important DNA-metabolizing enzymes, that is, topoisomerase I and II (Table 7).

### 12. The miscellaneous functional groups of organometallic compounds

Yin Zhang et al., reported the new phosphorescent rhenium(I) polypyridine fructose complex (167, 168). These complexes have been used to image BC cells, where fructose transporters are overexpressed (Fig. 6).

Stojković et al., reported three novel platinum(IV) complexes and their in vitro antiproliferative activity on tumor cell lines: human colon carcinoma HCT-116 and human breast carcinoma MDA-MB-231. Among these compounds, the highest antiproliferative effects had complex 169 on HCT-116 (IC$_{50}$ = 64.21 μM), until 170 had the highest effect on MDA-MB-231 (IC$_{50}$ = 68.023 μM) for 72 h of exposure (Fig. 6).

Two cis-isomers of platinum(IV) dichloride complexes composed of meta- and para-$N,N$-diphenyl pyridineamine...
derivatives (171 and 172) were prepared and found to be effective in blocking the growth and in inducing apoptosis in MCF-7 and MDA-MB-231, similar to cisplatin. In addition, compounds 171 and 172 also inhibited the migration of MDA-MB-231 cells possibly by affecting cytoskeletal organization membrane and vesicle flow, and cell polarity, as well as decreasing the levels of metabolic energy (ATP) (Fig. 6).148

13. Computer-aided synthesis of compounds

The above anticancer compounds are synthesized using traditional computational techniques, such as molecular docking, and in recent years, new approaches like the prediction of drug and drug targets candidates with mathematical and computational techniques was introduced.149–152 Advanced chemo-informatic tools were known as multitasking models for quantitative structure biological effect relationships.153 Such models are able to integrate multiple kinds of chemical and biological data,154–157 where many different kinds of pharmacological activities, pharmacokinetic parameters, and toxicity profiles are simultaneously predicted.158–165

A series of pyrazole based VEGFR-2 inhibitors supported by docking and in silico computational studies were designed on the basis of the hybridization approach, synthesized through facile synthetic methods, screened for in vitro antiproliferative activity against the HT-29 (human colon cancer) and MCF-7 (human breast cancer) cell lines and also studied for in vitro inhibitory activity against VEGFR-2 kinase. Among all the tested compounds, compound 173 (Fig. 7) emerged as a potent agent in the antiproliferative study against HT-29 and MCF-7 cells, with IC50 values of 2.36 and 6.59 \( \mu \)M, respectively. Moreover, the same compound exhibited the highest VEGFR-2 inhibitory activity with an IC50 value of 1.89 \( \mu \)M.166

The in vitro and in vivo results collectively suggest that 174 (Fig. 7), a new type of signal transducer and activator of transcription (STAT)3 inhibitors based on structural modifications on shikonin scaffold, guided by computational modeling, may serve as a promising lead compound for the further development of potential therapeutic anti-neoplastic agents. 174 was found to induce cell apoptosis in MDA-MB-231 cells, associated with the reduction of mitochondrial membrane potential, production of ROS and alteration of the levels of apoptosis-related proteins. Moreover, 174 inhibited constitutive/inducible STAT3 activation, transcriptional activity, nuclear translocation and downstream target genes expression in STAT3-dependent breast cancer cells MDA-MB-231.167

Based on the structures of PI3K inhibitor buparlisib and Hh inhibitor vismodegib, a series of hybrid structures were designed and synthesized utilizing rational drug design and computer-based drug design. Among several compounds, the representative compound 175 (Fig. 7) with the IC50 value of 3.61 \( \mu \)M displayed most excellent antiproliferative activities against MDA-MB-231 cell possibly through inhibiting both PI3K/Akt/mTOR and hedgehog signalings by inhibiting the phosphorylation of S6K and Akt as well as decreasing the SAG elevated expression of GlI1. Compound 175 could also induce apoptosis remarkably in T47D and MDA-MB-231 cells and showed significant inhibition on the migration of MDA-MB-231.168

Computational and experimental studies were applied to the discovery of a series of novel vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitors. Among all compounds, compound 176 (Fig. 7) behaved better than FDA approved drugs, sorafenib and sunitinib, in antiproliferative activity leukemia, non-small cell lung cancer (NSCLC), colon cancer, ovarian cancer and breast cancer cell lines, and it was better or comparable in safety. Compound 176 even demonstrated high potency on one of the drug-resistant cell lines responsible for ovarian cancer and cell lines contributing to prostate cancer, regarded as one of the VEGF/VEGFR pathway drug-resistant tumors.174

Computational docking methods were used to determine the binding modes of 3-(4-aminophenyl)-coumarin-7-O-sulfamate derivatives N-acylated with fluorinated analogs of benzoic or phenylacetic acid as steroid sulfatase (STS) inhibitors and to identify potential interactions between inhibitors and amino acid residues located in the active site of STS. Compounds 177 and 178 demonstrated the highest inhibitory effect in enzymatic STS assays, both with IC50 values of 0.18 \( \mu \)M (the IC50 value of coumarin-7-O-sulfamate is 1.38 \( \mu \)M, used as
Compound 178 exhibited the highest potency against the MCF-7 and T47D cell lines (GI50 values of 15.9 μM and 8.7 μM, respectively), in comparison with tamoxifen as a reference with 6.8 μM and 10.6 μM for MCF-7 and T47D cell lines, respectively. Despite the slightly lower activity of compounds 1 and 2 (both in enzymatic and cell-based experiments) compared to 180, analogues 179 and 180 proved to selectively inhibit the growth of ER- and PR-positive cell lines (Fig. 7).

Novel small molecules targeting Mps1 were designed by computer assisted docking analyses and synthesized. The lead compounds have strong anti-proliferative potential through Mps1/TTK inhibition in both basal and luminal BC cell lines, exhibiting IC50 values ranging from 0.05 to 1.0 μM. In addition, the lead compounds 181 and 182 inhibit Mps1 kinase enzymatic activity with IC50 values ranging from 0.356 μM to 0.809 μM, and inhibited Mps1-associated cellular functions such as centrosome duplication and the spindle checkpoint in triple negative breast cancer cells. The most promising analog, compound 181, significantly decreased tumor growth in nude mice containing Cal-51 triple negative breast cancer cell xenografts (Fig. 7).170

To identify potential natural allosteric inhibitor for Akt1, a seven-point pharmacophore model was generated and screened it through natural compound library. 182 (Fig. 7) as the best among selected molecules induced dose-dependent inhibition of MDA MB-231 and arrested them in G1 and sub-G phase. This was associated with down-regulation of anti-apoptotic protein Bcl-2, up-regulation of cleaved caspase-3 and PARP. Expression of p-Akt (Ser473) was also down-regulated which might be due to Akt1 inhibition in inactive conformation. the Akt1 and 182 interaction which was observed to have a dissociation constant of 0.246 μM.172

New benzimidazole derivatives were synthesized and assessed for anti-cancer. The computational studies affirmed that almost all of the inspected compounds meet the optimal requirements for good absorption and oral bioavailability. In vitro antitumor testing of these compounds toward liver cancer (HepG2), colon cancer (HCT-116) (IC50 = 0.014 mM) and breast cancer (MCF-7) (IC50 = 0.015 mM) cell lines revealed that compound 183 (Fig. 7) has the highest potency against the three tested cell lines.

A series of novel non-steroidal molecules containing 2-phenylindole scaffold and moiety of either imidazole or 1,2,4-triazole to enhance their binding capacity with the aromatase were designed and synthesized. Among these molecules, a compound 184 (IC50/aromatase: 14.1 nM; IC50/MCF-7: 325 μM) have the highest inhibitory activity to aromatase and low cytotoxicity. Molecular modelling and simulation techniques were performed to identify the binding modes of letrozole and 184 with the aromatase. Analysis of energy of the two compound–aromatase complexes revealed that the 184 has a low binding energy (strong binding affinity) to the aromatase as compared to letrozole, which was in accordance with the experimental results (Fig. 7).174

The synthesized 185 (Fig. 7) was evaluated as biological and anti-cancer active compound. Among all the tested
microorganisms and MCF-7 breast cancer cells, the synthesized nano-cellulose derivative is possible used as safety medicine for microbial infections and cancers. The cytotoxic index (IC_{50}) for MCF-7 breast cancers is 50 μg mL\(^{-1}\). Moreover, the computational study of ADMET (absorption, distribution, metabolism, elimination and toxic) properties, of the molecules showed that, this investigated nanocompound is good oral bioavailability.\(^{175}\)

### 14. Prospect

Due to the rapid social development and people’s life pressure, more and more patients were diagnosed with BC.\(^2,1^2\) With the increase in breast cancer patients, early treatment and early diagnosis were promoted. Once diagnosed, to determine chemotherapy is of great significance through differences in the genetic profile of the primary BC.\(^3,1^7\) What’s more, participation in an exercise and diet counseling program lead to loss of body fat, improved fitness and quality of life, and increased habitual physical activity in survivors of BC.\(^177,1^78\) And BC patients undergoing breast-conserving therapy had better outcome than modified radical mastectomy.\(^179\) Chemical treatment is particularly important, because of its advantages including higher rates of breast-conserving surgery and the possibility of measuring early in vivo response to systemic treatment.\(^180\) Thus, the discovery of new compounds is of particular importance, with promising anti-BC properties, which may be proven to be more effective and selective, and possibly free of unwanted side effects. In this review, the compounds designed and synthesized show little difference in the efficacy against breast cancer, whether using traditional computational techniques such as molecular docking or an innovative de novo design approach.

### 15. Conclusion

To sum up, based on the recent references, this review summarized some significant anti-BC compounds which are classified by functional groups. From this review we can see that a lot of people made many attempts to seek anti-BC compounds with more effective, more selective effects and lesser secondary actions. I hope that researchers can have a certain understanding and ideas on design and synthesis of anti-BC compounds through this review.

### Conflicts of interest

There are no conflicts to declare.

### References


39 N. N. El-Sayed, M. A. Abdelaziz, W. W. Wardakhan and R. M. Mohareb, The kynonovanegl reaction of cyanoacetylhydrazine with pregnenolone: synthesis of
thiophene, thieno[2,3-d]pyrimidine, 1,2,4-triazole, pyran and pyridine derivatives with anti-inflammatory and anti-ulcer activities, *Stemoids*, 2016, **107**, 98–111.


80. J. D. Brattlie, Progress towards the design and synthesis of novel anti-tumor neo-tanshinlactone analogues, The University of North Carolina at Chapel Hill, 2014.


103 P. Saha, S. Fortin, V. Leblanc, S. Parent, É. Asselin and G. Bérubé, Design, synthesis, cytotoxic activity and estrogen receptor α affinity of doxorubicin conjugates at


170 M. Dasko, M. Przybylowska, J. Rachon, M. Maslyk, K. Kubiński, M. Misiak, A. Składkowski and...


